Brief: Jasper Therapeutics Reports Positive Data From Beacon Study Of Briquilimab In Chronic Spontaneous Urticaria
08/01/2025 12:18
Jan 8 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS REPORTS POSITIVE DATA FROM BEACON
STUDY OF
BRIQUILIMAB IN CHRONIC SPONTANEOUS URTICARIA
* JASPER THERAPEUTICS INC - 66% MAINTAINED WELL CONTROLLED
DISEASE
AT 12 WEEKS IN 240MG COHORT
* JASPER THERAPEUTICS INC - DATA SUPPORTS COMMENCEMENT OF
CSU
REGISTRATIONAL PROGRAM EXPECTED TO COMMENCE SECOND HALF OF 2025
* JASPER THERAPEUTICS INC - 100% COMPLETE RESPONSES IN 240MG
COHORT AT 8 WEEKS
Source text: ID:nGNX3fqxwC
Further company coverage: JSPR.O
((Reuters.Brief@thomsonreuters.com))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma